| Ytd | 22.04% | |
| 1y | -11.74% |
| Open | 15.29 | Prev Close | 15.15 | Low | 15.29 | High | 16.00 | Mkt Cap | 1.83B |
| Vol | 1.20M | Avg Vol | 1.64M | EPS | -1.53 | P/E | N/A | Forward P/E | -12.70 |
| Beta | 0.92 | Short Ratio | 6.44 | Inst. Own | 88.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-23 | 50-d Avg | 16.14 | 200-d Avg | 13.46 | 1yr Est | 26.00 |
NVCR News
NVCR secures European approval for Optune Pax, expanding access to its pancreatic cancer treatment a
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the se
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically si
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Optune Pax® has rec
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
U.S. stocks traded higher on Thursday with the S&P 500 gaining 1% while tech shares surged 2.3%.
HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Buy and low
Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confir
Novocure (NASDAQ:NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluat